Lexeo Therapeutics, Inc. Common Stock (LXEO) Financials

$7.13

south_east
-$0.16 (-2.19%)
Day's range
$7.09
Day's range
$7.66

LXEO Income statement / Annual

Last year (2023), Lexeo Therapeutics, Inc. Common Stock's total revenue was $0.00, a decrease of 100.00% from the previous year. In 2023, Lexeo Therapeutics, Inc. Common Stock's net income was -$66.39 M. See Lexeo Therapeutics, Inc. Common Stock,s key income statements, including revenue, expenses, profit, and income.

Period FY-2023 FY-2022 FY-2021 FY-2020
Period Ended 12/31/2023 12/31/2022 12/31/2021 12/31/2020
Operating Revenue $0.00 $654,000.00 $1.66 M $518,476.00
Cost of Revenue $1.84 M $1.15 M $13,405.00 $0.00
Gross Profit -$1.84 M -$491,000.00 $1.64 M $518,476.00
Gross Profit Ratio 0 -0.75 0.99 1
Research and Development Expenses $53.13 M $49.16 M $45.12 M $4.32 M
General & Administrative Expenses $15.38 M $12.00 M $7.17 M $787,499.00
Selling & Marketing Expenses -$1.84 M $0.00 $0.00 $0.00
Selling, General & Administrative Expenses $13.54 M $12.00 M $7.17 M $787,499.00
Other Expenses $0.00 -$2,000.00 -$155.00 $4,241.00
Operating Expenses $66.67 M $61.16 M $52.29 M $5.11 M
Cost And Expenses $68.51 M $61.16 M $52.29 M $5.11 M
Interest Income $2.87 M $1.33 M $15,000.00 $0.00
Interest Expense $205,000.00 $91,000.00 $0.00 $147,150.00
Depreciation & Amortization $1.84 M $1.15 M $13,405.00 $4,241.00
EBITDA -$66.67 M -$58.04 M -$50.62 M -$4.58 M
EBITDA Ratio 0 -88.75 -30.54 -8.84
Operating Income Ratio 0 -92.52 -30.56 -8.85
Total Other Income/Expenses Net $2.12 M $1.23 M $15,000.00 -$565,000.00
Income Before Tax -$66.39 M -$59.28 M -$50.62 M -$5.15 M
Income Before Tax Ratio 0 -90.64 -30.55 -9.94
Income Tax Expense $0.00 $89,000.00 -$155.00 $147,150.00
Net Income -$66.39 M -$59.28 M -$50.62 M -$5.15 M
Net Income Ratio 0 -90.64 -30.55 -9.94
EPS -2.49 -2.4 -2.05 -0.21
EPS Diluted -2.49 -2.4 -2.05 -0.21
Weighted Average Shares Out $26.65 M $24.67 M $24.67 M $24.67 M
Weighted Average Shares Out Diluted $26.65 M $24.67 M $24.67 M $24.67 M
Link